Brief: Eli Lilly Phase 2 Data Showed Eloratzp Delivered Weight Loss Of Up To Average Of 54.1 Lbs (23.3%) At 48 Weeks In Adults With Obesity, Type 2 Diabetes
BRIEF-Eli Lilly Phase 2 Data Showed Eloratzp Delivered Weight Loss Of Up To Average Of 54.1 Lbs (23.3%) At 48 Weeks In Adults With Obesity, Type 2 Diabetes Nov 14 (Reuters) - Eli Lilly and Company LLY.N:
ELI LILLY: PHASE 2 DATA SHOWED ELORATZP DELIVERED WEIGHT LOSS OF UP TO AVERAGE OF 54.1 LBS (23.3%) AT 48 WEEKS IN ADULTS WITH OBESITY, TYPE 2 DIABETES
ELI LILLY: ELORATZP LOWERED A1C BY UP TO AVERAGE OF 2.9%, WITH UP TO 77% OF PARTICIPANTS ACHIEVING NORMAL BLOOD SUGAR LEVELS
ELI LILLY: PHASE 3 SURMOUNT-ADOLESCENTS SHOWED ZEPBOUND REDUCED BMI BY AVERAGE OF 21.4% IN ADOLESCENTS AGED 12 TO <18 YEARS WITH OBESITY
Source text: [ID:]
Further company coverage: LLY.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eli Lilly and
See all newsBiogen's anti-tau Alzheimer's drug benefits increase at 2 years
Eli Lilly’s $1.4 trln valuation is heavy with hope
Lilly signs cancer research deal with Stipple Bio worth up to $5.9 billion (updated)
Brief: Stipple Bio Enters Multi-Target Oncology Collaboration With Eli Lilly
Deals of the day-Mergers and acquisitions